225 related articles for article (PubMed ID: 26143615)
1. Safety and immunogenicity of a trivalent recombinant PcpA, PhtD, and PlyD1 pneumococcal protein vaccine in adults, toddlers, and infants: A phase I randomized controlled study.
Brooks WA; Chang LJ; Sheng X; Hopfer R;
Vaccine; 2015 Aug; 33(36):4610-7. PubMed ID: 26143615
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of pneumococcal protein vaccine candidates: monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine.
Bologa M; Kamtchoua T; Hopfer R; Sheng X; Hicks B; Bixler G; Hou V; Pehlic V; Yuan T; Gurunathan S
Vaccine; 2012 Dec; 30(52):7461-8. PubMed ID: 23123106
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults.
Seiberling M; Bologa M; Brookes R; Ochs M; Go K; Neveu D; Kamtchoua T; Lashley P; Yuan T; Gurunathan S
Vaccine; 2012 Dec; 30(52):7455-60. PubMed ID: 23131206
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials.
Leroux-Roels I; Devaster JM; Leroux-Roels G; Verlant V; Henckaerts I; Moris P; Hermand P; Van Belle P; Poolman JT; Vandepapelière P; Horsmans Y
Vaccine; 2015 Jan; 33(4):577-84. PubMed ID: 24176494
[TBL] [Abstract][Full Text] [Related]
5. Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults.
Pauksens K; Nilsson AC; Caubet M; Pascal TG; Van Belle P; Poolman JT; Vandepapelière PG; Verlant V; Vink PE
Clin Vaccine Immunol; 2014 May; 21(5):651-60. PubMed ID: 24599529
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults.
Kamtchoua T; Bologa M; Hopfer R; Neveu D; Hu B; Sheng X; Corde N; Pouzet C; Zimmermann G; Gurunathan S
Vaccine; 2013 Jan; 31(2):327-33. PubMed ID: 23153437
[TBL] [Abstract][Full Text] [Related]
7. Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical study.
Leroux-Roels G; Maes C; De Boever F; Traskine M; Rüggeberg JU; Borys D
Vaccine; 2014 Nov; 32(50):6838-46. PubMed ID: 24607003
[TBL] [Abstract][Full Text] [Related]
8. Trivalent pneumococcal protein vaccine protects against experimental acute otitis media caused by Streptococcus pneumoniae in an infant murine model.
Xu Q; Pryharski K; Pichichero ME
Vaccine; 2017 Jan; 35(2):337-344. PubMed ID: 27919628
[TBL] [Abstract][Full Text] [Related]
9. A Phase I, dose-escalation trial in adults of three recombinant attenuated Salmonella Typhi vaccine vectors producing Streptococcus pneumoniae surface protein antigen PspA.
Frey SE; Lottenbach KR; Hill H; Blevins TP; Yu Y; Zhang Y; Brenneman KE; Kelly-Aehle SM; McDonald C; Jansen A; Curtiss R
Vaccine; 2013 Oct; 31(42):4874-80. PubMed ID: 23916987
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.
Groome MJ; Koen A; Fix A; Page N; Jose L; Madhi SA; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
Lancet Infect Dis; 2017 Aug; 17(8):843-853. PubMed ID: 28483414
[TBL] [Abstract][Full Text] [Related]
11. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
[TBL] [Abstract][Full Text] [Related]
12. Formulation, stability and immunogenicity of a trivalent pneumococcal protein vaccine formulated with aluminum salt adjuvants.
Ljutic B; Ochs M; Messham B; Ming M; Dookie A; Harper K; Ausar SF
Vaccine; 2012 Apr; 30(19):2981-8. PubMed ID: 22381074
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: a phase II randomized clinical trial.
Prymula R; Pazdiora P; Traskine M; Rüggeberg JU; Borys D
Vaccine; 2014 May; 32(25):3025-34. PubMed ID: 24699466
[TBL] [Abstract][Full Text] [Related]
14. Safety, immunogenicity, and antibody persistence following an investigational Streptococcus pneumoniae and Haemophilus influenzae triple-protein vaccine in a phase 1 randomized controlled study in healthy adults.
Berglund J; Vink P; Tavares Da Silva F; Lestrate P; Boutriau D
Clin Vaccine Immunol; 2014 Jan; 21(1):56-65. PubMed ID: 24173029
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
[TBL] [Abstract][Full Text] [Related]
16. Trivalent pneumococcal protein recombinant vaccine protects against lethal Streptococcus pneumoniae pneumonia and correlates with phagocytosis by neutrophils during early pathogenesis.
Xu Q; Surendran N; Verhoeven D; Klapa J; Ochs M; Pichichero ME
Vaccine; 2015 Feb; 33(8):993-1000. PubMed ID: 25597944
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.
Groome MJ; Fairlie L; Morrison J; Fix A; Koen A; Masenya M; Jose L; Madhi SA; Page N; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
Lancet Infect Dis; 2020 Jul; 20(7):851-863. PubMed ID: 32251641
[TBL] [Abstract][Full Text] [Related]
18. Synchrony in serum antibody response to conserved proteins of Streptococcus pneumoniae in young children.
Ren D; Almudevar AL; Pichichero ME
Hum Vaccin Immunother; 2015; 11(2):489-97. PubMed ID: 25692218
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a novel multiple antigen pneumococcal vaccine in adults: A Phase 1 randomised clinical trial.
Entwisle C; Hill S; Pang Y; Joachim M; McIlgorm A; Colaco C; Goldblatt D; De Gorguette D'Argoeuves P; Bailey C
Vaccine; 2017 Dec; 35(51):7181-7186. PubMed ID: 29132988
[TBL] [Abstract][Full Text] [Related]
20. Contributions to protection from Streptococcus pneumoniae infection using the monovalent recombinant protein vaccine candidates PcpA, PhtD, and PlyD1 in an infant murine model during challenge.
Verhoeven D; Perry S; Pichichero ME
Clin Vaccine Immunol; 2014 Aug; 21(8):1037-45. PubMed ID: 24850621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
